Big Pharma has always had its ups and downs in the arena of public relations, known for offering the world its necessary medicine, drugs and cures— but never without the big paycheck behind the scenes.
And while many have turned away from trusting pharmaceutical brands and doctors who promote certain drugs, others have paved new roads to ensure patients get the help they deserve. Neuro-oncologist Max Temnik is here to join the latter and his potential cure for Parkinson’s Disease can revolutionize the industry, today.
A Moment of Science
In 2010, armed with a PhD in Chemistry, Temnik already understood that the human body is composed of minerals, which in turn are made of molecules and atoms. More importantly, he recognized that minerals, like humans, age through the gradual change of light’s weight and heavy isotopes found in the human body on a subatomic level.
In simpler terms: illness comes with aging.
Termnik’s initial steps involved patenting his ideas and collaborating with expert researchers to conduct preclinical studies that would satisfy the US Food and Drug Administration (FDA). He partnered with a pre-eminent research institution to validate his work.
“You may have the best idea in the world, but proof of concept is where the rubber meets the road,” Temnik expressed, importantly. “In the biotech world, the proof-of-concept ranges from animal models to clinical trials performed on humans— that is how we obtain genuine insight into the ultimate value of any proposed therapy.”
To date, Temnik has co-authored over 25 patents in isotope-selective modulation of the immune system, establishing the foundation for his companies to develop first-in-class therapies for treatment of various cancers, Alzheimer, and Parkinson’s diseases.
And all preclinical studies conducted by world-class researchers found nothing but promising results using Temnink’s novel isotope-selective treatment.
He was ready to make history.
A Quick Breakdown
Temnik’s treatment was tested against the apomorphine treatment, currently used to treat the ‘off’’ episodes in patients with advanced Parkinson’s disease.
The research demonstrated crucial effectiveness in preventing dopamine neuron degeneration, a crucial step in addressing Parkinson’s disease. Rats injected with the isotope-selective treatment showed an improvement in symptoms compared to those treated with apomorphine— an tell-tale sign that the therapy works.
Bottom line: preventing the destruction of dopaminergic neurons is a scientific breakthrough.
Moreover, researchers conducted what is called an immunohistochemical study of the number of TH-positive neurons in the midbrain. Tyrosine hydroxylase (or “TH”) is an enzyme that limits the synthesis of dopamine and is a classic marker of dopamine neurons. The studies revealed significant efficacy of the isotope-selective treatment in preventing the intensity of dopamine neuron degeneration in the substantia nigra of the brain’s left hemisphere.
The one issue Temnik faced, however, is that so far the study results have been achieved on rats— not humans.
What could he do to prove that it worked on both?
Welcome Nomax Therapeutics
Temnik was looking for the perfect counterpart to complement his studies and innovation.
In 2018, Temnik found a top molecular biology expert.
He is a neuro-oncologist and neurologist— ranked among the top 1% in the US by Castle Connolly Medical— and has long been fascinated by novel treatments for diseases. He was motivated by Temnik’s pursuit of trailblazing modern medicine and was excited to teamed up with Temnik to fight neurodegenerative diseases together.
Now we’ve hit 2021, the year Temnik founded Nomax Therapeutics, a Miami-based biotech company focused on developing experimental drugs for Parkinson’s disease. As mentioned above, the proprietary isotope-selective modulation of the immune system Temnki developed was the first-of-its-kind. The expert Temnik found joined as an independent primary investigator.
At Nomax Therapeutics, the mission was this: to restore dopamine-producing neurons to help patients’ motor symptoms come to well-controlled state and potentially achieve full recovery. The company pioneered a new approach to understanding Parkinson’s disease.
The researchers, with the help of renowned investigators, completed Phase 1 clinical trials on a small number of human patients. This was where science shook hands with the real world.
The Human Element
The first-in-human study aimed to determine the maximum tolerated dose (MTD), safety, and pharmacokinetics (PK) in patients with medical disorders. Multiple doses of the drug candidate were found safe and well tolerated by patients with various therapeutic conditions— and had no side effects.
Nomax Therapeutics became the name of the game.
And with this success, the company planned to generate $40 million through a securities offering by obtaining the required qualification from the U.S. Securities and Exchange Commission (tentatively in 2023).
Now, time is of the essence. Many Parkinson’s patients are fighting for their lives and their loved ones are fighting right alongside them, waiting for a cure. Temnik’s isotope-selective modulation of the immune system is currently the only therapy that acts upstream of the formation of neurotoxic proteins and neuron degeneration, potentially breaking the feedback cycle of age-related diseases and possibly altering the trajectory of aging and disease.
In other words, his therapy is the only therapy that offers hope to Parkinson’s patients and their families.
The Net-Net
With his groundbreaking approach to treating Parkinson’s disease, more families and their loved ones can be free of the slow, painful journey that the disease imparts upon thousands of people each year.
Indeed, nearly 90,000 patients get diagnosed every year in the U.S. and millions are affected world-wide.
Imagine a future free of debilitating disease. Temnik hasn’t just developed Big Pharma’s next big thing— he has cleared the way for life, for more time with loved ones.
This is about the human element— this is about our society as a whole, being one step closer to Parkinsons-free days.
“The next step is an initial public offering (IPO) to advance our development of our novel therapeutic portfolio,” Temnik said, passionately. “I want a world where Parkinson’s is just a disease of the past, and I firmly believe that Nomax Therapeutics will get us there.”
